Moderate

Primary sclerosing cholangitis (PSC)

PSC, sclerosing cholangitis, MRCP beading, IBD, cholangiocarcinoma, dominant stricture · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic progressive cholestatic disease with inflammation, fibrosis and multifocal strictures of intra- and extra-hepatic bile ducts, leading to biliary cirrhosis and portal hypertension. Strongly associated with inflammatory bowel disease (especially ulcerative colitis). High risk of cholangiocarcinoma, gallbladder and colorectal cancer. No proven disease-modifying drug; management is surveillance, endoscopic therapy of strictures, and transplant.

Red flags

  • New/worsening jaundice or rapid clinical deterioration (dominant stricture or cholangiocarcinoma)
  • Acute cholangitis: fever, RUQ pain, jaundice (Charcot triad) - needs urgent drainage
  • Rising CA19-9 / mass on imaging (cholangiocarcinoma or gallbladder cancer)
  • Decompensated cirrhosis / variceal bleed
  • Colorectal dysplasia/cancer on surveillance (IBD-PSC highest risk)

Assessment

Differential diagnosis

  • Secondary sclerosing cholangitis (ischaemic, post-surgical, recurrent cholangitis, IgG4)
  • IgG4-related sclerosing cholangitis (treatable with steroids - exclude)
  • Primary biliary cholangitis (small-duct, AMA positive)
  • Cholangiocarcinoma (dominant stricture)
  • Choledocholithiasis / biliary obstruction
  • Autoimmune hepatitis / PSC-AIH overlap (esp. children/young adults)

Investigations

  • LFTs - cholestatic pattern (raised ALP/GGT); fluctuating bilirubin
  • MRCP - investigation of choice: multifocal strictures and dilatation ('beaded' ducts); ERCP reserved for therapy or tissue
  • IgG4 level (exclude IgG4 cholangiopathy); autoimmune screen (ANA, SMA), immunoglobulins
  • Colonoscopy with biopsies in ALL (screen for IBD even if asymptomatic) at diagnosis
  • FBC, INR, fat-soluble vitamins, calcium/vitamin D; FibroScan/biopsy for small-duct PSC
  • Surveillance: annual CA19-9 + MRI/MRCP (or USS) for cholangiocarcinoma/gallbladder cancer; annual USS for gallbladder polyps; colonoscopy every 1-2 years if IBD

Management

  • Confirm with MRCP and exclude secondary/IgG4 causes (IgG4-related disease responds to steroids)
  • Colonoscopy to detect associated IBD in everyone; if IBD present, start annual/biennial surveillance colonoscopy (high colorectal cancer risk)
  • Manage cholestasis symptoms: pruritus ladder (cholestyramine -> rifampicin -> naltrexone/sertraline); replace fat-soluble vitamins; bone protection
  • Investigate any new jaundice, cholangitis, or rapid clinical change with urgent imaging - exclude DOMINANT STRICTURE and cholangiocarcinoma (ERCP with brushings/cholangioscopy + FISH, CA19-9)
  • ERCP with dilatation +/- short-term stenting for symptomatic dominant strictures; antibiotics for cholangitis
  • Cancer surveillance: annual cross-sectional imaging + CA19-9 (cholangiocarcinoma, gallbladder); cholecystectomy for any gallbladder polyp
  • Manage portal hypertension/varices; refer for liver transplant assessment for decompensation, recurrent cholangitis, intractable pruritus, or early cholangiocarcinoma per criteria

Drugs & doses

No proven disease-modifying drug - UDCA is NOT recommended at HIGH dose (28-30 mg/kg/day caused harm); low/moderate-dose UDCA sometimes used to improve biochemistry (no survival benefit) [verify local]
Pruritus: cholestyramine 4 g PO 1-4 times daily; then rifampicin 150-300 mg PO daily; then naltrexone or sertraline
Acute cholangitis: broad-spectrum IV antibiotics (per local policy, e.g. piperacillin-tazobactam) + biliary drainage (ERCP)
Fat-soluble vitamin (A, D, E, K) replacement; calcium + vitamin D; DEXA monitoring
IgG4 cholangiopathy (if that is the diagnosis instead): corticosteroids - hence exclude it first
Avoid high-dose UDCA (>28 mg/kg/day) - associated with worse outcomes

Disposition

Outpatient hepatology with structured cancer and IBD surveillance. Admit for cholangitis (urgent drainage), obstructive jaundice, suspected malignancy, or decompensation. Transplant assessment per criteria.

Complications & pitfalls

  • Biliary cirrhosis and portal hypertension
  • Cholangiocarcinoma (lifetime risk ~10-20%) and gallbladder carcinoma
  • Dominant strictures with recurrent bacterial cholangitis
  • Colorectal cancer (markedly raised in PSC-IBD)
  • Fat-soluble vitamin deficiency, metabolic bone disease
  • Recurrent PSC after transplant

Exam pearls

  • MRCP is the diagnostic test of choice (multifocal strictures/beading); reserve ERCP for therapy or tissue sampling of a dominant stricture.
  • Screen EVERY PSC patient for IBD with colonoscopy, and if IBD present perform surveillance colonoscopy every 1-2 years - colorectal cancer risk is very high.
  • Any new jaundice or clinical change = exclude a dominant stricture and CHOLANGIOCARCINOMA (CA19-9, MRI, ERCP brushings/FISH) - do not assume benign progression.
  • Do NOT use high-dose UDCA (28-30 mg/kg/day) - it caused harm; there is no proven disease-modifying therapy, so transplant is the only life-extending treatment.
  • Always exclude IgG4-related sclerosing cholangitis, which mimics PSC but responds to corticosteroids.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.